Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Eprodisate slows the progression of renal disease in patients with AA amyloidosis

Nature Clinical Practice Nephrology volume 3, pages 592–593 (2007)Cite this article

boxed-textDember LM et al. (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356: 2349–2360

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lachmann HJ et al. (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356: 2361–2371

    Article  CAS  Google Scholar 

  2. Gillmore JD et al. (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358: 24–29

    Article  CAS  Google Scholar 

  3. Gertz MA et al. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79: 319–328

    Article  Google Scholar 

  4. Zemer D et al. (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314: 1001–1005

    Article  CAS  Google Scholar 

  5. Tan AU Jr et al. (1995) Renal amyloidosis in a drug abuser. J Am Soc Nephrol 5: 1653–1658

    PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. AD Rule is an Assistant Professor of Medicine in the Division of Nephrology and Hypertension and the Division of Epidemiology, and N Leung is an Assistant Professor of Medicine in the Division of Nephrology and Hypertension, at the Mayo Clinic, Rochester, MN, USA.,

    Andrew D Rule & Nelson Leung

Authors
  1. Andrew D Rule
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nelson Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew D Rule.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rule, A., Leung, N. Eprodisate slows the progression of renal disease in patients with AA amyloidosis. Nat Rev Nephrol 3, 592–593 (2007). https://doi.org/10.1038/ncpneph0615

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0615

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing